<DOC>
	<DOCNO>NCT00985751</DOCNO>
	<brief_summary>This study ass safety , reactogenicity immunogenicity different formulation GSK Biologicals ' pneumococcal vaccine 2189242A administer alone combination 10-valent pneumococcal conjugate vaccine ( GSK1024850A vaccine ) 2-dose primary vaccination course follow booster dose healthy child age 12-23 month time first vaccination . Considering febrile reaction frequently observe follow pneumococcal vaccination , usually co-administered routine paediatric vaccine , primary study objective focus evaluate increase grade 3 fever ( i.e . rectal temperature &gt; 40.0°C ) .</brief_summary>
	<brief_title>Safety &amp; Immunogenicity Pneumococcal Vaccine 2189242A Children Aged 12-23 Months Time First Vaccination</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol Male female , include , 12 23 month age time first vaccination . Written inform consent obtain parents/LAR ( ) subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol study period start 30 day dose end 30 day dose vaccine ( ) . Previous vaccination S. pneumoniae since birth . History hypersensitivity reaction follow previous vaccination . Eczema history allergy Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) , include human immunodeficiency virus infection . A family history congenital hereditary immunodeficiency . Major congenital defect chronic illness . History neurologic disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature &gt; = 37.5°C oral axillary setting , &gt; = 38.0°C rectal setting . Subjects minor illness without fever may enrol discretion investigator . Administration immunoglobulins and/ blood product within 3 month precede first dose study vaccine plan use study period . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>immunogenicity</keyword>
	<keyword>toddler</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Haemophilus influenzae</keyword>
	<keyword>safety</keyword>
	<keyword>Streptococcus pneumoniae</keyword>
	<keyword>Streptococcus Pneumoniae Vaccines</keyword>
</DOC>